Cancer Res Treat.  2010 Dec;42(4):244-246.

Reversible Proximal Renal Tubular Dysfunction after One-Time Ifosfamide Exposure

• Kim YI
• Yoon JY
• Hwang JE
• Shim HJ
• Bae WK
• Cho SH
• Chung IJ

Abstract

The alkylating agent ifosfamide is an anti-neoplastic used to treat various pediatric and adult malignancies. Its potential urologic toxicities include glomerulopathy, tubulopathy and hemorrhagic cystitis. This report describes a case of proximal renal tubular dysfunction and hemorrhagic cystitis in a 67-year-old male given ifosfamide for epitheloid sarcoma. He was also receiving an oral hypoglycemic agent for type 2 diabetes mellitus and had a baseline glomerular filtration rate of 51.5 mL/min/1.73 m2. Despite mesna prophylaxis, the patient experienced dysuria and gross hematuria after a single course of ifosfamide plus adriamycin. The abrupt renal impairment and serum/urine electrolyte imbalances that ensued were consistent with Fanconi's syndrome. However, normal renal function and electrolyte status were restored within 14 days, simply through supportive measures. A score of 8 by Naranjo adverse drug reaction probability scale indicated these complications were most likely treatment-related, although they developed without known predisposing factors. The currently undefined role of diabetic nephropathy in adult ifosfamide nephrotoxicity merits future investigation.

Keyword

Ifosfamide; Proximal kidney tubules; Fanconi syndrome

MeSH Terms

Adult
Aged
Cystitis
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Doxorubicin
Drug Toxicity
Dysuria
Fanconi Syndrome
Glomerular Filtration Rate
Hematuria
Humans
Ifosfamide
Kidney Tubules, Proximal
Male
Mesna
Sarcoma
Doxorubicin
Ifosfamide
Mesna

Figure

• 

  Fig. 1 Bladder ultrasonographic finding shows mild and diffuse wall thickening of bladder wall.

Reference

1. Klastersky J. Side effects of ifosfamide. Oncology. 2003; 65(Suppl 2):7–10. PMID: 14586140.

2. Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer. 2007; 48:447–452. PMID: 16628552.

3. Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol. 1994; 12:159–165. PMID: 8270973.

4. Van Dyk JJ, Falkson HC, Van der Merwe AM, Falkson G. Unexpected toxicity in patients treated with iphosphamide. Cancer Res. 1972; 32:921–924. PMID: 4552918.

5. Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips PC, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006; 66:7824–7831. PMID: 16885387.

6. Walker RD. Cyclophosphamide induced hemorrhagic cystitis. J Urol. 1999; 161:1747. PMID: 10332428.

7. Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007; 23:303–312. PMID: 17225077.